Journal Article

Dose tailoring strategies in haemodialysis patients: a discussion of case histories

Werner Kleophas

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 20, issue suppl_6, pages vi31-vi36
Published in print June 2005 | ISSN: 0931-0509
Published online June 2005 | e-ISSN: 1460-2385 | DOI:
Dose tailoring strategies in haemodialysis patients: a discussion of case histories

Show Summary Details


Tailoring of the epoetin dose to the needs, clinical condition and circumstances of individual patients with renal anaemia offers potential for optimizing the benefits and costs of epoetin therapy. This can be achieved through alterations to dosing frequency, administration route and/or delivery device. Two case histories are presented to illustrate dose tailoring of epoetin therapy in daily clinical practice. The first patient was a man aged 23 years with renal failure secondary to vasculitis. Haemoglobin (Hb) levels were stable during treatment with subcutaneous (s.c.) epoetin-β. Switching to intravenous (i.v.) epoetin-β required, after a 5 month period of complex dose adjustments, a 50% increase in the dose of epoetin-β to maintain Hb levels. The second patient was a woman aged 50 years with diabetic nephropathy. She self-administered epoetin-β via the Reco-Pen® device to maintain stable Hb levels. Epoetin-β is approved for administration at dosing frequencies ranging from three times weekly to once every 2 weeks, is safe and effective whether administered by the s.c. or i.v. route and is available in a range of delivery devices. Epoetin-β therapy can be easily tailored according to the needs, preferences and circumstances of individual patients, thereby maximizing treatment outcomes.

Keywords: administration route; anaemia; device; dose tailoring; epoetin

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.